Ironwood Pharmaceuticals announced that its Board of Directors has appointed Tammi Gaskins, the company's current Senior Vice President and Chief Commercial Officer, as its next Chief Executive Officer, effective January 1, 2027. She will succeed Thomas McCourt, who is retiring as CEO on December 31, 2026, after 17 years with the company. Mr. McCourt will remain on the Board of Directors.
Key Details
- Incoming CEO: Tammi Gaskins will also be appointed to the Board of Directors. Her compensation package includes an annual base salary of $775,000, a 75% bonus target, and equity awards (RSUs and PSUs) with a combined target grant value of approximately $4,000,000.
- Outgoing CEO: Thomas McCourt will serve as a consultant to the company following his retirement, for an anticipated fee of $10,000 per month.
- Timeline: The CEO transition will be effective January 1, 2027. The appointment and retirement decisions were made by the board on October 12, 2026.